Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/24/30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/22/28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	1.05TCr 6.81TCr 910.7Cr 861.92Cr 783.11Cr 1.46TCr 1,00100Cr 1.47TCr 10TCr 3.97TCr 51TCr 3.93TCr 3.84TCr 1,62900Cr	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	1.05TCr 6.83TCr 913.26Cr 864.34Cr 785.31Cr 1.47TCr 1,00400Cr 1.47TCr 10TCr 3.98TCr 51TCr 3.94TCr 3.85TCr 1,63400Cr	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/24/30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/22/28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
26/21/26	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/20/17	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/20/07	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/20/30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/20/30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
14/20/14	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/19/25	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/19/25	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
13/19/13	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/19/12	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/19/31	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/21/02	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/20/17	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
29/20/29	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
27/20/27	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
27/20/27	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Share Price

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	13/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	01/03/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	164.41Cr
MERCK & CO., INC.	+1.55%	+1.69%	+81.35%	+36.86%	36TCr
MERCK KGAA	+0.04%	+0.19%	+22.57%	-18.10%	6.56TCr
HALOZYME THERAPEUTICS, INC.	+1.14%	+2.50%	+44.68%	+179.65%	1.24TCr
KYOWA KIRIN CO., LTD.	-0.29%	+2.94%	-6.00%	-16.51%	760.29Cr
SK BIOPHARMACEUTICALS CO., LTD.	+1.28%	-5.04%	-26.26%	-13.25%	449.16Cr
YUHAN CORPORATION	+0.26%	-1.77%	-33.30%	+7.78%	418.7Cr
BETTA PHARMACEUTICALS CO., LTD.	-1.48%	+0.87%	-32.20%	-15.17%	291.9Cr
SUPERNUS PHARMACEUTICALS, INC.	+3.72%	+2.95%	-4.20%	+46.84%	249.48Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.77%	-0.30%	-27.96%	-33.50%	193.24Cr
Average	+0.55%	+1.06%	+2.08%	+19.40%	4.66TCr
Weighted average by Cap.	+1.27%	+1.41%	+66.94%	+30.74%

	2017	2018
Net sales	3.02Cr 20Cr 2.63Cr 2.49Cr 2.26Cr 4.22Cr 288.91Cr 4.24Cr 30Cr 11Cr 146.83Cr 11Cr 11Cr 470.03Cr	3.95Cr 26Cr 3.44Cr 3.26Cr 2.96Cr 5.53Cr 378.24Cr 5.55Cr 39Cr 15Cr 192.22Cr 15Cr 15Cr 615.36Cr
Net income	-95.42L -6.21Cr -83.11L -78.66L -71.47L -1.34Cr -91Cr -1.34Cr -9.37Cr -3.62Cr -46Cr -3.58Cr -3.5Cr -148.67Cr	-52.85L -3.44Cr -46.03L -43.57L -39.58L -73.95L -51Cr -74.31L -5.19Cr -2.01Cr -26Cr -1.99Cr -1.94Cr -82Cr
Net Debt	1.81Cr 12Cr 1.57Cr 1.49Cr 1.35Cr 2.53Cr 172.89Cr 2.54Cr 18Cr 6.85Cr 88Cr 6.78Cr 6.63Cr 281.27Cr	2.94Cr 19Cr 2.56Cr 2.42Cr 2.2Cr 4.11Cr 281.42Cr 4.13Cr 29Cr 11Cr 143.02Cr 11Cr 11Cr 457.85Cr